- Home
- LUNG vs AQST Comparison
LUNG vs AQST Comparison
Compare LUNG & AQST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LUNG
- AQST
- Stock Information
- Founded
- LUNG 1995
- AQST 2004
- Country
- LUNG United States
- AQST United States
- Employees
- LUNG N/A
- AQST N/A
- Industry
- LUNG Industrial Specialties
- AQST Biotechnology: Pharmaceutical Preparations
- Sector
- LUNG Health Care
- AQST Health Care
- Exchange
- LUNG Nasdaq
- AQST Nasdaq
- Market Cap
- LUNG 299.3M
- AQST 274.4M
- IPO Year
- LUNG 2020
- AQST 2018
- Fundamental
- Price
- LUNG $7.76
- AQST $2.87
- Analyst Decision
- LUNG Strong Buy
- AQST Strong Buy
- Analyst Count
- LUNG 7
- AQST 7
- Target Price
- LUNG $12.64
- AQST $10.57
- AVG Volume (30 Days)
- LUNG 487.5K
- AQST 1.5M
- Earning Date
- LUNG 04-30-2025
- AQST 03-05-2025
- Dividend Yield
- LUNG N/A
- AQST N/A
- EPS Growth
- LUNG N/A
- AQST N/A
- EPS
- LUNG N/A
- AQST N/A
- Revenue
- LUNG $83,789,000.00
- AQST $57,561,000.00
- Revenue This Year
- LUNG $17.96
- AQST N/A
- Revenue Next Year
- LUNG $18.35
- AQST $35.72
- P/E Ratio
- LUNG N/A
- AQST N/A
- Revenue Growth
- LUNG 22.01
- AQST 13.80
- 52 Week Low
- LUNG $5.46
- AQST $2.24
- 52 Week High
- LUNG $10.01
- AQST $6.23
- Technical
- Relative Strength Index (RSI)
- LUNG 50.11
- AQST 47.99
- Support Level
- LUNG $6.97
- AQST $2.45
- Resistance Level
- LUNG $7.65
- AQST $3.06
- Average True Range (ATR)
- LUNG 0.67
- AQST 0.20
- MACD
- LUNG -0.18
- AQST 0.03
- Stochastic Oscillator
- LUNG 23.40
- AQST 60.66
About LUNG Pulmonx Corporation
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.
About AQST Aquestive Therapeutics Inc.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Sympazan Oral Film, Suboxone Sublingual Film, Exservan Oral Film, and Zuplenz. The product pipeline includes Libervant Buccal Film, AQST-108, and AQST-305. The majority of its revenue comes from the United States.